You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Trastuzumab in advanced breast cancer – a decade of experience in Germany
|
|---|---|
| Published in |
BMC Cancer, December 2014
|
| DOI | 10.1186/1471-2407-14-924 |
| Pubmed ID | |
| Authors |
Christian Jackisch, Winfried Schoenegg, Dietmar Reichert, Manfred Welslau, Johannes Selbach, Hanns-Detlev Harich, Hans Tesch, Tim Wohlfarth, Heidi Eustermann, Axel Hinke |
| Abstract |
Trastuzumab was registered in 2000 for the treatment of metastatic breast cancer, both as monotherapy and combination therapy with paclitaxel. In this prospective, non-interventional observation study, the 10-year experience with trastuzumab in the routine management of HER2-positive breast cancer was reviewed. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Venezuela, Bolivarian Republic of | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 2% |
| Unknown | 65 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 18% |
| Researcher | 10 | 15% |
| Student > Postgraduate | 7 | 11% |
| Student > Bachelor | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Other | 11 | 17% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 15% |
| Economics, Econometrics and Finance | 5 | 8% |
| Agricultural and Biological Sciences | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 16 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2014.
All research outputs
#7,349,257
of 22,774,233 outputs
Outputs from BMC Cancer
#2,030
of 8,282 outputs
Outputs of similar age
#106,489
of 360,800 outputs
Outputs of similar age from BMC Cancer
#47
of 165 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 8,282 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,800 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 165 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.